<DOC>
	<DOCNO>NCT00019656</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness perifosine treat patient refractory solid tumor hematologic cancer .</brief_summary>
	<brief_title>Perifosine Treating Patients With Refractory Solid Tumors Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose perifosine administer vary series load maintenance dos patient refractory solid tumor , non-Hodgkin 's lymphoma , chronic lymphocytic leukemia , myelodysplastic syndrome , Hodgkin 's lymphoma . - Determine profile adverse reaction ( include change laboratory parameter ) patient treat regimen . - Determine disease response may occur patient treated regimen . - Determine steady-state pharmacology pharmacokinetics regimen patient . OUTLINE : This dose-escalation study . Patients receive load dose oral perifosine day 1 follow maintenance dose 2-3 time daily begin day 2 3 continue day 21 . Courses repeat every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate load maintenance dos perifosine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 10 patient treat dose level . Patients follow every 3 month . PROJECTED ACCRUAL : A maximum 45 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor , nonHodgkin 's lymphoma , chronic lymphocytic leukemia , myelodysplastic syndrome , Hodgkin 's lymphoma effective standard therapeutic option require systemic therapy No history CNS neoplasm For prostate cancer : Tumor progression blockade testicular adrenal androgen At least 4 week since prior flutamide antiandrogens without disease improvement Leuprolide gonadotropinreleasing hormone maintain patient without orchiectomy Testosterone castrate range For breast cancer : At least 4 week since prior hormonal therapy evidence disease progression PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 50,000/mm^3 Absolute granulocyte count great 500/mm^3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No New York Heart Association class IIIV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No recent acute chronic gastrointestinal condition ( e.g. , stomach ulcer enteritis ) might affect tolerability drug absorption No allergic reaction medication structure similar perifosine No preexist retinal disease pathologic baseline electrooculogram No cataract would interfere normal vision require medical intervention No serious concurrent illness would preclude assessment drug effect PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover At least 2 month since prior UCN01 More 3 month since prior suramin Endocrine therapy : See Disease Characteristics No concurrent corticosteroid except physiological replacement antiemetic Radiotherapy : At least 4 week since prior radiotherapy ( 6 week boneseeking radioisotope ) recover Surgery : See Disease Characteristics Other : No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>